SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 15, 2011 08:16 ET

Potential Cancer Treatment From Cell Therapeutics and Oncothyreon Navigate Scrutiny

The Paragon Report Provides Equity Research on Cell Therapeutics and Oncothyreon

NEW YORK, NY--(Marketwire - Sep 15, 2011) - The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cell Therapeutics, Inc. (NASDAQ: CTIC) and Oncothyreon, Inc. (NASDAQ: ONTY). Access to the full company reports can be found at:

Cancer has emerged as the world's most expensive disease -- costing the global economy more than a trillion dollars a year. While the developers of cancer treatment could strike it rich with a blockbuster product, there are significant risks for these biotech companies. Reuters published research from BioMed Tracker and BIO, claiming that the cancer drug success rate is a mere 4.7 percent. Recently, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards, recommending that sponsors generally be required to conduct randomized trials rather than single-arm studies, and that there be more extensive postmarketing studies to confirm clinical benefit.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Oncothyreon recently announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. According to Oncothyreon, "PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway."

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. The company says that its drug candidate Pixantrone "is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents."

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at